Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine (692342) [GSK 692342] in HIV-Positive Adults.

Trial Profile

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine (692342) [GSK 692342] in HIV-Positive Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs GSK 692342 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jul 2009 Results were presented at the 5th International AIDS Society Conference on HIV Pathogenesis and Treatment (IAS 2009) held in Cape Town, South Africa.
    • 10 Jun 2009 Actual patient number (37) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top